Other Clinical Trial - Rebound Exercise in Neurological Disorders

Status Recruiting

Clinical Trial Summary

This study will be a pretest-posttest interventional trial investigating the use of rebound exercise in community-dwelling individuals with neurological disorders.

Clinical Trial Description

Neurological disorders are linked to various problems, including but not limited to movement impairments, balance, fear of falls, reduced exercise tolerance, loss of muscle strength, reduced functional independence, sedentary behaviour and reduced quality of life. These impairments can lead to physical deconditioning, functional dependency and extreme disability if left unmanaged, creating the need for prompt treatment. Rebound exercise is an effective and safe form of aerobic exercise that has been successfully used in some populations. It can be included in rehabilitating people with neurological disorders for its beneficial effects on humans and minimal stress on the heart and joints. Its fun-giving experience makes it easier to engage regularly compared to traditional exercise tools that may feel like a task. It is also more affordable and less time-consuming than other standard modalities. The few available studies on rebound exercise in neurological disorders were mostly in inpatients, and evidence is scarce on the use of rebound exercise in community-dwelling individuals with neurological disorders. It is thus necessary to investigate its use in the community context as well as the minimal effective dosage of the intervention. This study will investigate the frequency of rebound exercise necessary to effect changes in physiological and functional outcomes such as heart rate, blood pressure, physical activity level, walking speed, risk of falls, cognitive function and quality of life. The enrolled participants will undergo 12 weeks of rebound exercise training once or twice weekly, depending on their frequency choice. Ethical approval has been sought and obtained from the Research Ethics Committee of Buckinghamshire New University. Eligible volunteer participants will be asked to sign the informed consent after the study has been explained to them. They will be assured of data confidentiality by anonymising their information and will also be informed of their right to withdraw at any point. ;

Study Design

Related Conditions & MeSH terms

Nervous System Diseases
Neurological Diseases or Conditions

Clinical Trial Details

NCT number	NCT05526508
Study type	Interventional
Source	Buckinghamshire New University
Contact	Adaora J Okemuo, M.Sc
Phone	07883733407
Email	Adaora.Okemuo@bucks.ac.uk
Status	Recruiting
Phase	N/A
Start date	December 12, 2022
Completion date	July 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03128086` - Weaning From Mechanical Ventilation in Neurological Patients	N/A
Recruiting	`NCT04581577` - Perceptions of the Clinical and Psychosocial Impact of Covid-19 in Patients With Neuromuscular and Neurological Disorders
Active, not recruiting	`NCT05742087` - Neuropathy and Anti-GFAP Antibodies
Recruiting	`NCT05645003` - Transcranial Magnetic Stimulation Therapy in Neuropathic Painful Spinal Cord Injury Patients	N/A
Withdrawn	`NCT04377425` - COVID-19 Prevalence and Cognitive Deficits in Neurological Patients
Withdrawn	`NCT01898975` - A Gray Zone Approach to Stroke Volume Variation Derived From NICOM	N/A
Active, not recruiting	`NCT03480581` - Impact of Reverse vs. Forward ICARE Training Interventions	N/A
Completed	`NCT04061616` - Transcultural Validation of the Physical Activity Scale for Individuals With Physical Disabilities (PASIPD) in French: The PASIPD-Fr	N/A
Recruiting	`NCT04706481` - Archival of Human Biological Samples in CU-Med Biobank
Completed	`NCT05169788` - Rehabilitation Through the Italian Version of the Teen Online Problem-Solving (TOPS) Program	N/A
Completed	`NCT03619642` - Reliability, Validity and Clinical Utility of a Robotic Assessment for Proprioception	N/A
Recruiting	`NCT05086380` - Modulation of Sense of Agency With Non-invasive Brain Stimulation and Mindfulness-based Stress Reduction Therapy	N/A
Recruiting	`NCT04866251` - Prevalence of Gag Reflex in Healthy Persons and Across Different Patient Groups and Its Relevance in Dysphagia Screening	N/A
Not yet recruiting	`NCT05796037` - An Observational Study of Patients Living With Chronic Neurological Diseases
Recruiting	`NCT03777267` - Cereset Research Exploratory Study	N/A
Completed	`NCT05097066` - Patterns and Outcomes of Neurosurgery in England Over a Five-year Period

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.